SVR in patients with HCV genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir - Hallo friendsTHE LEK NEWS, In the article you read this time with the title SVR in patients with HCV genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir, We have prepared this article for you to read and retrieve information therein. Hopefully the contents of postings Article culture, Article economy, Article health, Article healthy tips, Article news, Article politics, Article sports, We write this you can understand. Alright, good read.

Title : SVR in patients with HCV genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir
link : SVR in patients with HCV genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir

SVR in patients with HCV genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir

Aliment Pharmacol Ther. 2018 Nov 22. https://doi.org/10.1111/apt.15043 . [Epub ahead of print]

Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir

Emily Nguyen Sam Trinh Huy Trinh Huy Nguyen Khanh Nguyen Aivien Do Brian Levitt Son Do My Nguyen Treta Purohit Eugenie Shieh Mindie H. Nguyen 

First published: 22 November 2018

View full article online: https://onlinelibrary.wiley.com/doi/full/10.1111/apt.15043

Abstract

BACKGROUND: 

Hepatitis C virus (HCV) genotype 6 (GT 6) is the predominant genotype among certain Asian populations. The availability of newer DAA options is limited in many parts of Asia.

AIM: 

To compare sustained virologic response (SVR-12) rates between ledipasvir and sofosbuvir (LDV+SOF) and velpatasvir+SOF (SOF+VEL) for patients with HCVGT6 infection.

METHOD: 

Retrospective study of consecutive adult HCVGT6 patients identified via ICD 9 code: 070.5 from United States treatment centers. Treatment was LDV+SOF or SOF+VEL for 8-24 weeks. A 1:1 propensity score matching (PSM) on HCV RNA, cirrhosis, alanine aminotransferase, aspartate aminotransferase, platelets, and fibrosis score was conducted among the treatment-naïve HCVGT6 patients to balance groups and isolate treatment effects.

RESULTS: 

After exclusion criteria, 149 patients remained (n = 135 treatment-naïve; n = 14 treatment-experienced). The mean age was 63.8 ± 10.2 years, 66.9% male, and 93.9% Vietnamese. In treatment-naïve arm, 52.2% LDV+SOF cohort were cirrhotic compared to 11.6% SOF+VEL cohort (P < 0.0001). SVR-12 for LDV+SOF was 96.4% and 100% for the SOF+VEL cohort (P = 0.22). SVR-12 for cirrhotic patients was 95.4% (n = 41/43) for LDV+SOF and 100.0% (n = 5/5) for SOF+VEL (P = 0.62). After PSM (n = 33 per group), LDV+SOF SVR-12 rate was 97.0% compared to SOF+VEL SVR-12 of 100% (P = 0.31). The treatment-experienced group (n = 14), were all treated with LDV+SOF-SVR-12 of 92.3%.

CONCLUSION: 

Whether treatment-naïve, treatment-experienced, or cirrhotic patients with HCV GT 6 residing in the US had excellent outcomes when treated with SOF+VEL or LDV+SOF. Since LDV+SOF is more readily available globally, our results may provide clinicians with a treatment option when cost and availability limit the treatment choice.

Full-Text Online:

https://onlinelibrary.wiley.com/doi/full/10.1111/apt.15043

Thus Article SVR in patients with HCV genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir

That's an article SVR in patients with HCV genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir This time, hopefully can give benefits to all of you. well, see you in posting other articles.

You are now reading the article SVR in patients with HCV genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir with the link address https://theleknews.blogspot.com/2018/11/svr-in-patients-with-hcv-genotype-6.html

Tweet

Subscribe to receive free email updates: